SCHEMBL1764438

SCHEMBL1764438

COc1ccc(-c2oc3c(OC)c(OC)c(OC)c(OC)c3c(=O)c2O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 4/20 0.67
MAPT P10636 4/20 0.67
GAA P10253 2/20 0.67
ABCG2 Q9UNQ0 5/20 0.57
ABCB1 P08183 4/20 0.57
MAOA P21397 2/20 0.57
CYP1A1 P04798 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP1B1 Q16678 1/20 0.57
FTO Q9C0B1 1/20 0.57
MAPK1 P28482 1/20 0.57
PPARG P37231 1/20 0.57
CYP3A4 P08684 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
PKM P14618 2/20 0.56
HSD17B10 Q99714 2/20 0.54
TP53 P04637 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28984281 0.88 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTGAAABCG2
SCHEMBL5137806 0.87 MAPT (0.87) ALDH1A1KDM4EMAPTGAAABCG2
Prudomestin SCHEMBL30977124 0.85 ABCB1 (0.65) ALDH1A1KDM4EMAPTGAAABCG2
5-Hydroxyauranetin SCHEMBL4066374 0.85 MAPT (0.71) ALDH1A1KDM4EMAPTGAAABCG2
SCHEMBL30049379 0.85 MAPT (0.62) ALDH1A1KDM4EMAPTGAAABCG2
SCHEMBL30050183 0.84 MAPT (0.65) ALDH1A1KDM4EMAPTGAAABCG2
SCHEMBL16894648 0.84 ABCG2 (0.66) ALDH1A1KDM4EMAPTGAAABCG2
Tambulin SCHEMBL4742083 0.83 ALDH1A1 (0.64) ALDH1A1MAPTABCG2ABCB1MAOA
Tambulin SCHEMBL29728591 0.83 ALDH1A1 (0.64) ALDH1A1MAPTABCG2ABCB1MAOA
Natsudaidai SCHEMBL890712 0.83 ABCG2 (0.79) ALDH1A1KDM4EMAPTGAAABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115315194-B Hydroxy-and methoxy-substituted flavones and use thereof 弗门尼舍有限公司 2024-06-21 CN claimed
EP-4258899-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE Firmenich SA (CH) 2023-10-18 EP claimed
CN-115315194-A Hydroxy-and methoxy-substituted flavones and their use 弗门尼舍有限公司 2022-11-08 CN claimed
WO-2022189155-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2022-09-15 WO claimed
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions WLLGEN, INC. (US) 2014-02-06 US claimed
EP-2010194-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS Rutgers, The State University of New Jersey (US) 2009-01-07 EP claimed
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions WELLGEN, INC. 2007-11-29 US claimed
WO-2007109071-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO claimed
CN-115315194-B Hydroxy-and methoxy-substituted flavones and use thereof 弗门尼舍有限公司 2024-06-21 CN disclosed
EP-4258899-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE Firmenich SA (CH) 2023-10-18 EP disclosed
CN-115315194-A Hydroxy-and methoxy-substituted flavones and their use 弗门尼舍有限公司 2022-11-08 CN disclosed
WO-2022189155-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONES AND THEIR USE FIRMENICH SA (CH) 2022-09-15 WO disclosed
CN-112830917-A Hydroxylated polymethoxyflavone and preparation method thereof 五邑大学 2021-05-25 CN disclosed
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions WLLGEN, INC. (US) 2014-02-06 US disclosed
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions WELLGEN, INC. 2007-11-29 US disclosed
WO-2007109071-A2 HYDROXYLATED POLYMETHOXYFLAVONE COMPOSITIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO disclosed
US-20070088078-A1 Methods for managing adipocyte fat accumulation WELLGEN, INC. 2007-04-19 US disclosed
WO-2007024982-A2 METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION WELLGEN, INC. (US) 2007-03-01 WO disclosed
US-20070042972-A1 Compositions and methods for optimizing exercise recovery RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-02-22 US disclosed
WO-2006127996-A2 COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042972-A1 Compositions and methods for optimizing exercise recovery GYS1, PYGM, PRDX5 ALDH1A1 3163/4885KDM4E 121/4885MAPT 4515/4885
US-20070088078-A1 Methods for managing adipocyte fat accumulation FABP4, PLIN5, PLIN3 ALDH1A1 1272/4885KDM4E 248/4885MAPT 3872/4885
US-20070275106-A1 Hydroxylated polymethoxyflavone compositions PLIN5, FANCF, COXFA4 ALDH1A1 1794/4885KDM4E 1277/4885MAPT 4329/4885
US-20140039044-A1 Hydroxylated Polymethoxyflavone Compositions PLIN5, FANCF, COXFA4 ALDH1A1 1794/4885KDM4E 1277/4885MAPT 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.